REPARE THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.45 USD | +2.99% |
|
+7.81% | -52.74% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,261 | 880.2 | 617.3 | 307.5 | 146.4 | - | - |
| Enterprise Value (EV) 1 | 927.3 | 538.3 | 273.3 | 83.92 | -83.04 | -178.6 | 146.4 |
| P/E ratio | -12.9 x | -7.45 x | -21.3 x | -3.27 x | -1.29 x | -1.1 x | -0.93 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 9,341 x | 116 x | 4.68 x | 6.01 x | 3.24 x | 12.4 x | 3.97 x |
| EV / Revenue | 6,869 x | 70.8 x | 2.07 x | 1.64 x | -1.84 x | -15.1 x | 3.97 x |
| EV / EBITDA | -17.4 x | -5.02 x | -15.3 x | -0.73 x | 0.66 x | 0.98 x | -1.2 x |
| EV / FCF | -119 x | -6.15 x | -976 x | -0.65 x | 1.06 x | 1.4 x | -1.13 x |
| FCF Yield | -0.84% | -16.3% | -0.1% | -154% | 93.9% | 71.7% | -88.8% |
| Price to Book | 4.41 x | 3.06 x | 2.21 x | 1.45 x | 0.54 x | 0.52 x | - |
| Nbr of stocks (in thousands) | 36,765 | 41,735 | 41,962 | 42,130 | 42,445 | - | - |
| Reference price 2 | 34.30 | 21.09 | 14.71 | 7.300 | 3.450 | 3.450 | 3.450 |
| Announcement Date | 04/03/21 | 01/03/22 | 28/02/23 | 28/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 0.135 | 7.6 | 131.8 | 51.13 | 45.21 | 11.79 | 36.86 |
| EBITDA 1 | - | -53.4 | -107.2 | -17.82 | -114.3 | -126.2 | -181.8 | -121.9 |
| EBIT 1 | - | -54.3 | -108.7 | -19.8 | -116.2 | -126.4 | -168.3 | -164.7 |
| Operating Margin | - | -40,223.7% | -1,429.74% | -15.02% | -227.3% | -279.56% | -1,427.23% | -446.78% |
| Earnings before Tax (EBT) 1 | - | -54.74 | -108.6 | -13.9 | -103.2 | -118.9 | -170.8 | -169.5 |
| Net income 1 | -27.22 | -53.42 | -106.9 | -29.05 | -93.8 | -115.9 | -170.8 | -169.5 |
| Net margin | - | -39,568.15% | -1,406.68% | -22.03% | -183.44% | -256.29% | -1,448.03% | -459.81% |
| EPS 2 | - | -2.660 | -2.830 | -0.6900 | -2.230 | -2.677 | -3.135 | -3.705 |
| Free Cash Flow 1 | - | -7.805 | -87.49 | -0.28 | -129.1 | -78 | -128 | -130 |
| FCF margin | - | -5,781.48% | -1,151.13% | -0.21% | -252.47% | -172.52% | -1,085.43% | -352.7% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 29/05/20 | 04/03/21 | 01/03/22 | 28/02/23 | 28/02/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.278 | 6.877 | 0.408 | 0.679 | 112.5 | 18.2 | 5.678 | 30.25 | 2.159 | 13.05 | 38.4 | 2.404 | 2.571 | 2.908 | 4.703 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -31.68 | -28.73 | -34.83 | -38.73 | 73.4 | -19.63 | -34.68 | -12.26 | -38.42 | -30.87 | -4.599 | -40.97 | -41.03 | -41.3 | -39.42 |
| Operating Margin | -11,395.32% | -417.83% | -8,536.52% | -5,704.57% | 65.22% | -107.88% | -610.8% | -40.52% | -1,779.43% | -236.58% | -11.98% | -1,704.28% | -1,595.87% | -1,419.93% | -838.27% |
| Earnings before Tax (EBT) 1 | -31.6 | -28.7 | -34.72 | -38.06 | 75.52 | -16.63 | -31.32 | -8.836 | -35.18 | -27.84 | -3.682 | -38.4 | -38.8 | -39.42 | -38.29 |
| Net income 1 | -30.89 | -28.29 | -34.76 | -38.09 | 75.46 | -31.66 | -34.94 | -11.95 | -18.88 | -28.03 | -2.342 | -38.15 | -38.55 | -39.18 | -38.29 |
| Net margin | -11,112.23% | -411.37% | -8,518.87% | -5,610.16% | 67.05% | -173.96% | -615.38% | -39.49% | -874.43% | -214.84% | -6.1% | -1,586.89% | -1,499.68% | -1,346.99% | -814.22% |
| EPS 2 | -0.8300 | -0.7100 | -0.8300 | -0.9100 | 1.710 | -0.7500 | -0.8300 | -0.2800 | -0.4500 | -0.6700 | -0.0160 | -0.8860 | -0.8980 | -0.8960 | -0.8900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 10/11/21 | 01/03/22 | 05/05/22 | 04/08/22 | 09/11/22 | 28/02/23 | 09/05/23 | 09/08/23 | 09/11/23 | 28/02/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 334 | 342 | 344 | 224 | 229 | 325 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -7.81 | -87.5 | -0.28 | -129 | -78 | -128 | -130 |
| ROE (net income / shareholders' equity) | - | -44.4% | -37.2% | -10.2% | -38.2% | -43% | -48.9% | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 7.770 | 6.890 | 6.650 | 5.030 | 6.400 | 6.630 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | 2.24 | 1.69 | 0.6 | 1.94 | 1 | 1 | 5 |
| Capex / Sales | - | 1,657.04% | 22.24% | 0.46% | 3.79% | 2.21% | 8.48% | 13.57% |
| Announcement Date | 29/05/20 | 04/03/21 | 01/03/22 | 28/02/23 | 28/02/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
3.45
USD
Average target price
15.33
USD
Spread / Average Target
+344.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -52.74% | 146M | |
| +25.69% | 47.9B | |
| +46.90% | 41.42B | |
| -3.46% | 40.7B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- RPTX Stock
- Financials Repare Therapeutics Inc.
